ELI LILLY & Co is 523.3x more valuable than Immunome Inc. by market capitalization ($1.072 T vs $2.05 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | IMNM | LLY |
|---|---|---|
| Market cap | $2.05 B | $1.072 T |
| US-listed rank | #2082 | #10 |
| Revenue (latest FY) | $6.94M | $65.18B |
| Net income (latest FY) | -$212.39M | $20.64B |
| Net margin | -3060.0% | 31.7% |
| P/E (trailing FY) | - | 51.9 |
| SEC filings | 416 | 989 |
ELI LILLY & Co is 523.3x more valuable than Immunome Inc. by market capitalization ($1.072 T vs $2.05 B).
In their latest fiscal years, Immunome Inc. reported $6.94M in revenue while ELI LILLY & Co reported $65.18B.
Full pages: Immunome Inc. and ELI LILLY & Co, or browse the full rankings.